If the measuring stick is going to be the same for a botanical as for a single-molecule pharmaceutical drug, we have problems. That's one of the reasons for the delay in getting the evidence we need.
There are two reasons why we do those studies. One is to convince Health Canada, or whoever's going to determine that a new product can come onto the market, that the drug is efficacious—it's going to work for that problem better than a placebo will. Two is that it's safe. Is that not correct?